Designed to transform the art and science of fat transfer, Viality addresses significant unmet market need
This product will be commercially available in the United States beginning in Q1 of 2023. (Credit: Jennifer Burk on Unsplash)
Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery launched the Viality lipoaspirate wash system at the Beauty Through Science meeting in NYC this past Saturday. This product will be commercially available in the United States beginning in Q1 of 2023.
Fat transfer, a procedure used to relocate fat from one area of the body to another where volume is desired, has increased in popularity in recent years and is used in both breast reconstruction and augmentation procedures, as well as across other body areas such as the buttocks, hands and face. Despite fat transfer’s growing popularity, physician satisfaction with the currently available fat transfer systems on the market is low. Developed by researchers at Harvard and Massachusetts General Hospital, the Viality system solves this market need. Viality is the only fat transfer system with AuraClens, a proprietary cleansing mechanism (lipoaspirate wash) to better retain viable fat leading to more predictable results. In addition, the design enables gentle fat mixing to protect viable fat cells from damage and a super absorbent foam layer that removes unwanted fluids and maximizes the concentration of fat. The device also has the capability of processing from 50 to more than 1000cc in a single run.
“As the first-of-its-kind technology, Viality will escalate the standards for fat transfer across the industry,” said board-certified Plastic Surgeon Dr. Brad Calobrace, who is a principal investigator for the ongoing Viality clinical study. “Viality has brought innovation and intention together in the operating room. The use of this system has revealed a new, extraordinary approach to fat transfer, providing better predictability and results for my patients.”
Studies have shown that Viality produced an average of 94% cell viability and 89% average fat concentration with low processing time and increased volume for reinjection. In addition, the AuraClens concentrating wash was shown in a 20-patient study to improve fat retention by more than 31% compared to saline rinse.
“At Sientra ‘good’ has never been enough and we are thrilled to be able to offer plastic surgeons, and their patients, this new innovation that will elevate the standards of plastic surgery and the entire fat transfer category.” said Ron Menezes, President and CEO of Sientra. “We believe that the launch of Viality will significantly increase Sientra’s addressable TAM and add meaningful top-line revenue growth in 2023 as we initially target the breast reconstruction and augmentation market while looking to expand into other body areas.”
Source: Company Press Release